Table 3.
First three therapy approaches in acute and lymphoma types of ATL patients.
| First therapy approaches in ATL patients | ||||
|---|---|---|---|---|
| Subtypes of ATL | Patients treated, n (% of patients) | CHOP-like alone n (% of treated patients) | AZT/IFN alone n (% of treated patients) | AZT/IFN plus chemotherapy n (% of treated patients) |
| Acute (n = 23) | 18 (78%) | 5 (27%) | 9 (50%) | 4 (22%) |
| Lymphoma (n = 14) | 12 (85%) | 6 (50%) | 1 (8%) | 5 (42%) |
| Chronic (n = 1) | 1 (100%) | 0 | 1 (100%) | 0 |
| PCT-ATL (n = 1) | 1 (100%) | 0 | 1 (100%) | 0 |
| Second line therapy approaches | |||||
|---|---|---|---|---|---|
| CHOP-like alone n (% of treated patients) | DHAOx n (% of treated patients) | Bendamustine and idelalisib n (% of treated patients) | Ritonavir and interferon n (% of treated patients) | ||
| Acute (n = 23) | 6 (26%) | 6 (100%) | 0 | 0 | 0 |
| Lymphoma (n = 14) | 5 (36%) | 2 (40%) | 1 (20%) | 1 (20%) | 1 (20%) |
| Chronic (n = 1) | 0 | 0 | 0 | 0 | 0 |
| PCT-ATL (n = 1) | 1 (100%) | 1 (100%) | 0 | 0 | 0 |
| Third line therapy approaches | ||||
|---|---|---|---|---|
| DHAP n (% of treated patients) | Lamivudine-zidovudine-Interferon-Etoposide n (% of treated patients) | Bendamustine and idelalisib n (% of treated patients) | ||
| Acute (n = 23) | 2 (9%) | 1 (50%) | 0 | 1 (50%) |
| Lymphoma (n = 14) | 2 (14%) | 1 (50%) | 1 (50%) | 0 |
| Chronic (n = 1) | 0 | 0 | 0 | 0 |
| PCT-ATL (n = 1) | 0 | 0 | 0 | 0 |
Abbreviations: CHOP: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; AZT/IFN: Zidovudine combined with PEGylated Interferon alpha; ATL: Adult T-cell Leukemia/Lymphoma; DHAOx: Dexamethasone, Cytarabin, Oxaliplatin; DHAP: Dexamethasone, Cytarabin and Cisplatin.